Depression and Anxiety in Rheumatoid Arthritis (DEAR)

University of Pavia

Status: Completed

Conditions: Depression; Anxiety; Rheumatoid Arthritis

Treatments: Other: Hospital Anxiety and Depression Scale (HADS) questionnaire

Study type: Observational

Funder types: Other

Identifiers

NCT02122406

31748\2009 progetto lorhen

Details and patient eligibility

About

The primary endpoint of this study is to evaluate the prevalence of anxiety and depressive disorders, and their relationship with disease activity, in patients with rheumatoid arthritis treated with biological drugs

Full description

The prevalence of anxiety and depressive disorders will be assesed with the HADS questionnaire at the time of the visit

Enrollment: 200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age >18 years
• diagnosis of rheumatoid arthritis according to 2010 Classification American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Criteria
• being able to compile questionnaire
• current treatment with biological disease-modifying antirheumatic drug

Exclusion criteria

• Current treatment for anxiety or depressive disorder

Trial design

200 participants in 1 patient group

Patients RA-BIO

Description:

Patients with rheumatoid arthritis treated with biological drugs (infliximab, adalimumab, etanercept, abatacept, tocilizumab, golimumab, certolizumab, rituximab)

Treatment:

Other: Hospital Anxiety and Depression Scale (HADS) questionnaire